Table 1 (abstract P268). The estimated prevalence of juvenile localised Scleroderma in the United States
From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)
Year | Total Children (N) | Diagnosis Code for Localized Scleroderma (N) | No Diagnosis Code for Systemic Sclerosis or Mixed Connective Tissue Disease (N) | Use of Methotrexate | Estimated Prevalence per 10,000 Children [95% CI] |
|---|---|---|---|---|---|
2010 | 5,894,628 | 2064 | 2006 / 2064 | 75 / 2006 | 3.4 [3.3-3.6] |
2011 | 6,231,475 | 2269 | 2222 / 2269 | 86 / 2222 | 3.6 [3.4-3.7] |
2012 | 6,278,118 | 2198 | 2154 / 2198 | 68 / 2154 | 3.4 [3.3-3.6] |
2013 | 4,950,018 | 1732 | 1692 / 1732 | 61 / 1692 | 3.4 [3.3-3.6] |
2014 | 4,933,523 | 1620 | 1588 / 1620 | 71 / 1588 | 3.2 [3.1-3.4] |